Related Experiment Video
Updated: Jan 7, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens
Anne-Geneviève Marcelin1, Cathia Soulie1, Marc Wirden1
1Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Paris, France.
Objective:
To assess the prevalence and patterns of treatment-emergent resistance-associated mutations (RAMs) in people with HIV (PWH) with ≥1 prior regimen experiencing virologic failure (VF) with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/lamivudine (DTG/3TC), or cabotegravir/rilpivirine (CAB + RPV) in an observational setting.
Design:
A noninterventional, multicenter, retrospective, observational study was conducted between January 1, 2022 and December 31, 2024 using a national French multicenter database of genotypic resistance assays performed at confirmed VF.
Methods:
VF was defined as 2 consecutive HIV-1 plasma viral loads of >50 copies/mL. Genotypic resistance assays were performed using Sanger sequencing. Treatment-emergent RAMs were characterized using the 2024 ANRS algorithm. Clinical history, virologic history, and demographic data were collected from medical records during standard clinical follow-up.
Results:
A total of 6523 PWH were followed over 3 years. The prevalence of VF during follow-up was 6% with B/F/TAF, 5% with DTG/3TC, and 5% with CAB + RPV. The prevalence of treatment-emergent RAMs at VF were 3% with B/F/TAF, 15% with DTG/3TC, and 32% with CAB + RPV. Dual treatment-emergent integrase strand transfer inhibitor (InSTI) and nucleoside reverse transcriptase inhibitor (NRTI) RAMs were observed with B/F/TAF and DTG/3TC, while dual treatment-emergent nonnucleoside reverse transcriptase inhibitor (NNRTI) and InSTI RAMs were observed with CAB + RPV.
Conclusions:
The overall prevalence of VF was low for all regimens. B/F/TAF was associated with a numerically lower prevalence of RAMs at VF compared with DTG/3TC and CAB + RPV. These observational findings highlight the importance of monitoring resistance patterns to optimize HIV treatment outcomes.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Treatment Resistant Cancers
Viral Mutations
Size and Structure of Viral Genomes
Subviral Agents

